Table 1.
Characteristics of patients with ICI therapy–associated diabetes
| Characteristics | Patients | Severe outcomes |
|---|---|---|
| All | 735 (100) | 183 (100) |
| Sex | ||
| Male | 415 (56.46) | 107 (58.47) |
| Female | 262 (35.65) | 69 (37.70) |
| Not specified | 58 (7.89) | 7 (3.83) |
| Age (years) | ||
| <65 | 284 (38.64) | 79 (43.17) |
| ≥65 | 333 (45.31) | 93 (50.82) |
| Not specified | 118 (16.05) | 11 (6.01) |
| Cancer types | ||
| Melanoma | 248 (33.74) | 57 (31.14) |
| Lung | 191 (25.99) | 62 (33.88) |
| Renal | 91 (12.38) | 21 (11.48) |
| Others | 205 (27.89) | 43 (23.50) |
| Reporting year* | ||
| 2015 | 17 (2.31) | 9 (4.92) |
| 2016 | 71 (9.66) | 20 (10.93) |
| 2017 | 117 (15.92) | 27 (14.75) |
| 2018 | 199 (27.07) | 54 (29.51) |
| 2019 | 331 (45.04) | 73 (39.89) |
| Treatment regimens | ||
| Anti–PD-1 therapy | 466 (64.40) | 127 (69.40) |
| Anti–PD-L1 therapy | 34 (4.63) | 6 (3.28) |
| Anti–CTLA-4 therapy | 16 (2.18) | 2 (1.09) |
| Combination therapy of anti–CTLA-4/anti–PD-1/anti–PD-L1 | 219 (29.79) | 48 (26.23) |
Data are n (%).
*
Reporting year refers to the year of “latest FDA received date” in the FAERS.